Press release
Biologic & Biosimilar RA Drugs Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportunities
Biologic & Biosimilar RA Drugs
What Is the Projected Growth of the Biologic & Biosimilar RA Drugs Market?
In recent times, there's been a robust growth in the biologic & biosimilar ra drugs market size. The market, which is projected to expand from $13.99 billion in 2024 to $14.71 billion in 2025, is expected to witness a compound annual growth rate (CAGR) of 5.2%. This growth during the historic period can be ascribed to various factors such as rate of market adoption, results of clinical trials, changes in market share, outcomes pertaining to long-term patients, and pricing strategies.
The market size of biologic and biosimilar ra drugs is projected to witness a robust expansion in the coming years, and it is predicted to reach a value of $19.51 billion by 2029, growing at a Compound Annual Growth Rate (CAGR) of 7.3%. The surge in the forecasted period is linked to the escalation in biologic drug development, market rivalry, healthcare regulations, user choices, and research and development in the clinical sector. The main trends for the forecast period comprise increase in competition within the biosimilar market, tailored medicine and precision therapy, advancements in the system of delivering drugs, focus on safety and effectiveness, and patient-focused healthcare.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9255
What Are the Different Biologic & Biosimilar RA Drugs Market Segments?
The biologic & biosimilar RA drugs market covered in this report is segmented -
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster ovary* (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp
What Are the Primary Drivers Shaping the Biologic & Biosimilar RA Drugs Market?
The progression of the biologics and biosimilar RA drugs market is being propelled by a surge in the elderly population and a higher occurrence of rheumatoid arthritis. Individuals who are 60 years of age or older constitute this older demographic. An autoimmune disease where a person's immune system harms its healthy cells is known as rheumatoid arthritis, and it affects the person's joints predominantly. It is more prevalent among the elderly as their immune system weakens with age. When compared to traditional medication, biologics and biosimilar RA drugs prove to be more effective for rheumatoid arthritis treatment. For instance, the World Health Organization, a specialized health agency of the United Nations based in Switzerland, reported that as of 2020, the world's population of those aged 60 and over was approximately 1 billion, and this number is projected to rise to 1.4 billion by 2030 and 2.1 billion by 2050. Additionally, the Centers for Disease Control and Prevention, the US government's public health agency, estimates that the number of American adults with arthritis will rise to 78.4 million by 2040, with 34.6 million facing limitations due to arthritis-related activities. Consequently, the increasing elderly population and rising RA cases are propelling the biologics and biosimilar RA drugs market's growth.
Which Companies Are Leading in the Biologic & Biosimilar RA Drugs Market?
Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.
What Are the Major Trends Shaping the Biologic & Biosimilar RA Drugs Market?
Emerging advancements are becoming a significant factor in the rising prominence of the biologic & biosimilar RA drugs market. Large firms in the market are honing in on the creation of biosimilar therapies such as Dual Concentration Biosimilar Options as a cost-effective alternative. For example, Organon, a healthcare company based in the US, teamed up with Samsung Bioepis, a biopharmaceutical company from South Korea, in July 2023 to launch HADLIMA. This drug, a biosimilar of Humira (adalimumab), is accessible in the US in both high and low concentrations and is designed to improve affordability and access for sufferers of autoimmune diseases. HADLIMA is offered at an 85% markdown compared to Humira, enabling expanded access to patients. The Arthritis Foundation recognizes it, and HADLIMA For You, a patient assistance program, provides resources for education and co-pay assistance. Suitable for a range of conditions like rheumatoid arthritis and Crohn's disease, HADLIMA offers both citrate-free high concentration (100 mg/mL) and citrate-inclusive low concentration (50 mg/mL), ensuring undisturbed continuity of care for patients.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report
What Are the Top Revenue-Generating Geographies in the Biologic & Biosimilar RA Drugs Market?
North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Biologic & Biosimilar RA Drugs Market?
2. What is the CAGR expected in the Biologic & Biosimilar RA Drugs Market?
3. What Are the Key Innovations Transforming the Biologic & Biosimilar RA Drugs Industry?
4. Which Region Is Leading the Biologic & Biosimilar RA Drugs Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biologic & Biosimilar RA Drugs Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportunities here
News-ID: 3977267 • Views: …
More Releases from The Business Research Company
Key Trends Reshaping the Agricultural Biotechnology Market: Innovative Biotechno …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Agricultural Biotechnology Market Size Growth Forecast: What to Expect by 2025?
In recent times, the agricultural biotechnology market has witnessed considerable growth. It is anticipated to expand from $44.82 billion in 2024 to $49.18 billion in 2025, at a Compound Annual Growth Rate (CAGR) of 9.7%. This significant increase…
Health-Conscious Trends Propel Growth In Sorghum Seed Market: Transformative For …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Sorghum Seed Industry Market Size Be by 2025?
Over recent years, the sorghum seed market has experienced a significant uptick in growth. The market is projected to escalate from a value of $2.06 billion in 2024 to $2.18 billion in 2025, advancing at a compound annual…
Steady Expansion Forecast for Meat Market, Projected to Reach $1599.32 Billion b …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Meat Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The expansion of the meat market has been robust in the last few years. The market which is projected to be at $1133.29 billion in 2024 is expected to escalate to $1217.95 billion in 2025 with…
Grain Farming Industry Outlook 2025-2029: Market Set to Cross $1633.78 Billion M …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Grain Farming Market Size By 2025?
In the past few years, the size of the grain farming market has significantly expanded. It is projected to rise from $1139.2 billion in 2024 to $1226.32 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.6%.…
More Releases for Drugs
Generic Drugs Market Application Anti-Infective Drugs, Anti-Arthritis Drugs, Ant …
Generic drugs are the medications that are developed to be similar to a medicine that is already commercially available in the market with a brand name. The generic drug is similar to the medicine available in terms of dosage, safety and strength, mode of administration, quality and intended use. Due to the similarities, generic drugs are capable of treating various diseases. Generic drugs are most cost effective than the branded…
Cytotoxic Drugs Market Growing Demand for Antimetabolite Drugs
According to Precision Business Insights (PBI), the latest report, the cytotoxic drugs market is expected to be valued at USD 15,927.2 million in 2022 and is poised to grow at a significant CAGR of 2.2% over 2022-2028. The primary drivers of the expansion of the global cytotoxic drugs market include the increasing prevalence of cancer diseases, the increasing use and approval of cytotoxic drugs, and the increasing consumption of alcohol…
Global Antithrombotic Drugs Market | Global Antithrombotic Drugs Industry | Glob …
Antithrombotic drugs are special drugs that help to prevent the formation of thrombus or clot. These drugs are used to reduce the formation of blood clots by reducing the capability of body to form a blood clot. Antithrombotic drugs act by preventing the production of vitamin K in the liver. Anticoagulant, antiplatelet, and thrombolytic agents are different types of antithrombotic agents that act by different clotting processes. Arterial & venous…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
Hepatitis Drugs Market by Therapeutics, Diagnostics, Patient, Drugs Policy
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.
Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market
Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest…
Epilepsy Drugs Market by Country, Drugs, Company & Forecast
For More Information:
https://renub-research.blogspot.com/2019/04/the-factors-that-are-driving-global.html
Epilepsy is a chronic disease in which patient’s brain activities become abnormal due to seizures. Seizure is an unexpected rush of electrical activity in the brain. Seizure is categorized by two types - generalized seizures and focal or partial seizures. Generalized seizures affect the whole brain whereas focal or partial seizures affect just one part of the brain. Global epilepsy drugs market is expected to cross US$…
